Let's be optimistic! Imagine having two businesses in operation in the 1Q'15. With commissions on marijuana, gambling and retail sales added to Emesyl, the cash position should be substantial. Furthermore, undisclosed corporate expansion is a possibility and the introduction of a second product from Itonis Pharmaceuticals. All these developments, in time, will lead to an advance to Nasdaq and the attraction of more investors.
News 
Market Data 
Discover 
